Role of gonadotropin-releasing hormone analogues in metastatic male breast cancer

Results from a pooled analysis

Luigi Di Lauro, Laura Pizzuti, Maddalena Barba, Domenico Sergi, Isabella Sperduti, Marcella Mottolese, Carla Azzurra Amoreo, Franca Belli, Patrizia Vici, Valerie Speirs, Daniele Santini, Ruggero De Maria, Marcello Maugeri-Saccà

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Background: Male breast cancer is a rare malignancy. Despite the lack of prospectively generated data from trials in either the adjuvant or metastatic setting, patients are commonly treated with hormone therapies. Much controversy exists over the use of gonadotropin-releasing hormone analogues in metastatic male breast cancer patients. We conducted this study to provide more concrete ground on the use of gonadotropin-releasing hormone analogues in this setting. Methods: We herein present results from a pooled analysis including 60 metastatic male breast cancer patients treated with either an aromatase inhibitor or cyproterone acetate as a monotherapy (23 patients) or combined with a gonadotropin-releasing hormone analogue (37 patients). Results: Overall response rate was 43.5 % in patients treated with monotherapy and 51.3 % with combination therapy (p∈=∈0.6). Survival outcomes favored combination therapy in terms of median progression-free survival (11.6 months versus 6 months; p∈=∈0.05), 1-year progression-free survival rate (43.2 % versus 21.7 %; p∈=∈0.05), median overall survival (29.7 months versus 22 months; p∈=∈0.05), and 2-year survival rate (64.9 % versus 43.5 %; p∈=∈0.05). Conclusions: In metastatic male breast cancer patients, the combined use of gonadotropin-releasing hormone analogues and aromatase inhibitors or antiandrogens seems to be associated with greater efficacy, particularly in terms of survival outcomes, compared with monotherapy. Collectively, these results encourage considering these agents in the metastatic setting.

Original languageEnglish
Article number53
JournalJournal of Hematology and Oncology
Volume8
Issue number1
DOIs
Publication statusPublished - May 17 2015

Fingerprint

Male Breast Neoplasms
Gonadotropin-Releasing Hormone
Aromatase Inhibitors
Disease-Free Survival
Survival
Survival Rate
Cyproterone Acetate
Androgen Antagonists
Therapeutics
Hormones

Keywords

  • Aromatase inhibitors
  • Cyproterone acetate
  • Gonadotropin-releasing hormone analogue
  • Male breast cancer
  • Metastatic disease

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research
  • Molecular Biology

Cite this

Role of gonadotropin-releasing hormone analogues in metastatic male breast cancer : Results from a pooled analysis. / Di Lauro, Luigi; Pizzuti, Laura; Barba, Maddalena; Sergi, Domenico; Sperduti, Isabella; Mottolese, Marcella; Amoreo, Carla Azzurra; Belli, Franca; Vici, Patrizia; Speirs, Valerie; Santini, Daniele; De Maria, Ruggero; Maugeri-Saccà, Marcello.

In: Journal of Hematology and Oncology, Vol. 8, No. 1, 53, 17.05.2015.

Research output: Contribution to journalArticle

Di Lauro, L, Pizzuti, L, Barba, M, Sergi, D, Sperduti, I, Mottolese, M, Amoreo, CA, Belli, F, Vici, P, Speirs, V, Santini, D, De Maria, R & Maugeri-Saccà, M 2015, 'Role of gonadotropin-releasing hormone analogues in metastatic male breast cancer: Results from a pooled analysis', Journal of Hematology and Oncology, vol. 8, no. 1, 53. https://doi.org/10.1186/s13045-015-0147-z
Di Lauro, Luigi ; Pizzuti, Laura ; Barba, Maddalena ; Sergi, Domenico ; Sperduti, Isabella ; Mottolese, Marcella ; Amoreo, Carla Azzurra ; Belli, Franca ; Vici, Patrizia ; Speirs, Valerie ; Santini, Daniele ; De Maria, Ruggero ; Maugeri-Saccà, Marcello. / Role of gonadotropin-releasing hormone analogues in metastatic male breast cancer : Results from a pooled analysis. In: Journal of Hematology and Oncology. 2015 ; Vol. 8, No. 1.
@article{6e083083e1a242758c66846f86b4f4c7,
title = "Role of gonadotropin-releasing hormone analogues in metastatic male breast cancer: Results from a pooled analysis",
abstract = "Background: Male breast cancer is a rare malignancy. Despite the lack of prospectively generated data from trials in either the adjuvant or metastatic setting, patients are commonly treated with hormone therapies. Much controversy exists over the use of gonadotropin-releasing hormone analogues in metastatic male breast cancer patients. We conducted this study to provide more concrete ground on the use of gonadotropin-releasing hormone analogues in this setting. Methods: We herein present results from a pooled analysis including 60 metastatic male breast cancer patients treated with either an aromatase inhibitor or cyproterone acetate as a monotherapy (23 patients) or combined with a gonadotropin-releasing hormone analogue (37 patients). Results: Overall response rate was 43.5 {\%} in patients treated with monotherapy and 51.3 {\%} with combination therapy (p∈=∈0.6). Survival outcomes favored combination therapy in terms of median progression-free survival (11.6 months versus 6 months; p∈=∈0.05), 1-year progression-free survival rate (43.2 {\%} versus 21.7 {\%}; p∈=∈0.05), median overall survival (29.7 months versus 22 months; p∈=∈0.05), and 2-year survival rate (64.9 {\%} versus 43.5 {\%}; p∈=∈0.05). Conclusions: In metastatic male breast cancer patients, the combined use of gonadotropin-releasing hormone analogues and aromatase inhibitors or antiandrogens seems to be associated with greater efficacy, particularly in terms of survival outcomes, compared with monotherapy. Collectively, these results encourage considering these agents in the metastatic setting.",
keywords = "Aromatase inhibitors, Cyproterone acetate, Gonadotropin-releasing hormone analogue, Male breast cancer, Metastatic disease",
author = "{Di Lauro}, Luigi and Laura Pizzuti and Maddalena Barba and Domenico Sergi and Isabella Sperduti and Marcella Mottolese and Amoreo, {Carla Azzurra} and Franca Belli and Patrizia Vici and Valerie Speirs and Daniele Santini and {De Maria}, Ruggero and Marcello Maugeri-Sacc{\`a}",
year = "2015",
month = "5",
day = "17",
doi = "10.1186/s13045-015-0147-z",
language = "English",
volume = "8",
journal = "Journal of Hematology and Oncology",
issn = "1756-8722",
publisher = "BioMed Central Ltd.",
number = "1",

}

TY - JOUR

T1 - Role of gonadotropin-releasing hormone analogues in metastatic male breast cancer

T2 - Results from a pooled analysis

AU - Di Lauro, Luigi

AU - Pizzuti, Laura

AU - Barba, Maddalena

AU - Sergi, Domenico

AU - Sperduti, Isabella

AU - Mottolese, Marcella

AU - Amoreo, Carla Azzurra

AU - Belli, Franca

AU - Vici, Patrizia

AU - Speirs, Valerie

AU - Santini, Daniele

AU - De Maria, Ruggero

AU - Maugeri-Saccà, Marcello

PY - 2015/5/17

Y1 - 2015/5/17

N2 - Background: Male breast cancer is a rare malignancy. Despite the lack of prospectively generated data from trials in either the adjuvant or metastatic setting, patients are commonly treated with hormone therapies. Much controversy exists over the use of gonadotropin-releasing hormone analogues in metastatic male breast cancer patients. We conducted this study to provide more concrete ground on the use of gonadotropin-releasing hormone analogues in this setting. Methods: We herein present results from a pooled analysis including 60 metastatic male breast cancer patients treated with either an aromatase inhibitor or cyproterone acetate as a monotherapy (23 patients) or combined with a gonadotropin-releasing hormone analogue (37 patients). Results: Overall response rate was 43.5 % in patients treated with monotherapy and 51.3 % with combination therapy (p∈=∈0.6). Survival outcomes favored combination therapy in terms of median progression-free survival (11.6 months versus 6 months; p∈=∈0.05), 1-year progression-free survival rate (43.2 % versus 21.7 %; p∈=∈0.05), median overall survival (29.7 months versus 22 months; p∈=∈0.05), and 2-year survival rate (64.9 % versus 43.5 %; p∈=∈0.05). Conclusions: In metastatic male breast cancer patients, the combined use of gonadotropin-releasing hormone analogues and aromatase inhibitors or antiandrogens seems to be associated with greater efficacy, particularly in terms of survival outcomes, compared with monotherapy. Collectively, these results encourage considering these agents in the metastatic setting.

AB - Background: Male breast cancer is a rare malignancy. Despite the lack of prospectively generated data from trials in either the adjuvant or metastatic setting, patients are commonly treated with hormone therapies. Much controversy exists over the use of gonadotropin-releasing hormone analogues in metastatic male breast cancer patients. We conducted this study to provide more concrete ground on the use of gonadotropin-releasing hormone analogues in this setting. Methods: We herein present results from a pooled analysis including 60 metastatic male breast cancer patients treated with either an aromatase inhibitor or cyproterone acetate as a monotherapy (23 patients) or combined with a gonadotropin-releasing hormone analogue (37 patients). Results: Overall response rate was 43.5 % in patients treated with monotherapy and 51.3 % with combination therapy (p∈=∈0.6). Survival outcomes favored combination therapy in terms of median progression-free survival (11.6 months versus 6 months; p∈=∈0.05), 1-year progression-free survival rate (43.2 % versus 21.7 %; p∈=∈0.05), median overall survival (29.7 months versus 22 months; p∈=∈0.05), and 2-year survival rate (64.9 % versus 43.5 %; p∈=∈0.05). Conclusions: In metastatic male breast cancer patients, the combined use of gonadotropin-releasing hormone analogues and aromatase inhibitors or antiandrogens seems to be associated with greater efficacy, particularly in terms of survival outcomes, compared with monotherapy. Collectively, these results encourage considering these agents in the metastatic setting.

KW - Aromatase inhibitors

KW - Cyproterone acetate

KW - Gonadotropin-releasing hormone analogue

KW - Male breast cancer

KW - Metastatic disease

UR - http://www.scopus.com/inward/record.url?scp=84930678440&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930678440&partnerID=8YFLogxK

U2 - 10.1186/s13045-015-0147-z

DO - 10.1186/s13045-015-0147-z

M3 - Article

VL - 8

JO - Journal of Hematology and Oncology

JF - Journal of Hematology and Oncology

SN - 1756-8722

IS - 1

M1 - 53

ER -